Déjà Vu, We Have All Been Here Before: OPDP Issues Its Second Warning Letter in 2021
By EsqSocial Corporation 26/02/21
Well, that was fast. Fresh off issuing its first Warning Letter of 2021,1 the Food and Drug Administration’s Office of Prescription Drug Promotion (“OPDP”) struck again. OPDP sent the Warning Letter to the drug company a day after issuing the first. If the agency keeps this pace, we will be preparing a number of Bulletins in 2021.2 The second Warning Letter includes many recurring themes of unlawful promotional areas. In addition, OPDP sent an Untitled Letter to the company in 2019 for similar...
By: Arnall Golden Gregory LLP